Cellular Biomedicine Group (CBMG) Expands Cell Production

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
70
Cellular Biomedicine Group (CBMG) Expands Cell Production With Capacity to Produce CAR-T Therapies to Treat 10,000 Cancer Patients Annually

SHANGHAI, China and CUPERTINO, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biomedicine firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, is pleased to announce the signing of a ten-year lease of a 113,038 square feet building located in the “Pharma Valley” in Shanghai Zhangjiang High-Tech Park. The new GMP facility that will be built on these premises will consist of 40,000 square feet dedicated to advanced cell manufacturing.  By the end of 2017, the Company anticipates that the new Zhangjiang, an expanded Wuxi, and Beijing GMP facilities combined will have 70,000 square feet, and the Company expects that it will be capable of supporting simultaneous clinical trials for five different CAR-T and stem cell products, or approximately the ability to treat 10,000 cancer patients and 10,000 stem cell patients per year.

“We are very excited to continue to add to our in-house manufacturing capabilities. This new development, once built out, will substantially expand our total production facility’s square footage across three key cities in China. In conjunction with the upcoming expanded GMP facility in Wuxi for clinical grade Plasmid and Viral Vectors bank production, we will have an integrated Chemistry, Manufacturing, and Controls (“CMC”) process for CAR-T production through predominately closed and automated systems.  We believe this will enable us to serve scaled-up demand for our current and future CAR-T clinical studies and will allow CBMG to move quickly and efficiently from R&D into manufacturing of CAR-T cells for clinical use, IND filings, and future commercialization,” said Tony (Bizuo) Liu, Chief Executive Officer of CBMG.

CBMG recently announced the approval and commencement of patient enrollment in China for its CARD-1 Phase I clinical trial utilizing its optimized proprietary C-CAR011 construct of CD19 chimeric antigen receptor T-cell (CAR-T) therapy for the treatment of patients with refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as announcing promising interim 3-month safety data from its Phase I clinical trial in China for AlloJoin™ off-the-shelf allogeneic stem cell therapy for Knee Osteoarthritis (KOA).

About Cellular Biomedicine Group (CBMG) Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. Our immuno-oncology and stem cell projects are the result of research and development by CBMG’s scientists and clinicians from both China and the United States. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include risks inherent in doing business, trends affecting the global economy, including the devaluation of the RMB by China in August 2015 and other risks detailed from time to time in CBMG’s reports filed with the Securities and Exchange Commission, quarterly reports on form 10-Q, current reports on form 8-K and annual reports on form 10-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contacts: Sarah Kelly  Director of Corporate Communications, CBMG +1 408-973-7884 sarah.kelly@cellbiomedgroup.com Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 vivian.chen@grayling.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 495

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 0

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 269

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 287

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 399

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 176

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 0

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Cryptocurrency Through Sustainable Mining Solutions

Updated Category News Views 132

Ripple and Dogecoin Capture Market Attention Recently, Ripple, known by its trading symbol XRP, regained significant visibility in the cryptocurrency market following a major legal victory against a regulatory body. This resurgence has reignited interest among investors and enthusiasts alike. Meanwhile, Dogecoin has been experiencing a renaissance, driven by the ambitious...

Continue Reading
General Dynamics Sees Growth in Q2 Earnings and Revenue

Updated Category News Views 147

General Dynamics Q2 Financial Highlights General Dynamics reported remarkable financial results for the second quarter of 2025, showcasing a revenue of $13 billion, which marks an 8.9% increase compared to the same quarter last year. The company achieved operating earnings of $1.3 billion, translating to a diluted earnings per share (EPS) of $3.74, reflecting a 14.7%...

Continue Reading
FIU Shines as a Top Public University in New Ranking

Updated Category News Views 77

FIU Ranks High in TIME's New College List Alright, listen up. The latest college buzz isn't just noise—Florida International University (FIU) is sitting pretty at No. 23 among public universities in TIME's first crack at America's Best Colleges for the 2026-2027 term. They're also punching in at No. 62 overall out of 500 schools. For a university that's been...

Continue Reading
Recent Net Asset Value Disclosure for Hargreave Hale AIM VCT

Updated Category News Views 174

Understanding the Latest Net Asset Value Announcement The Hargreave Hale AIM VCT PLC has recently made an important announcement regarding its Net Asset Value (NAV). This provides valuable insights for investors and stakeholders looking to evaluate the fund's performance. It is crucial for those following this investment vehicle to stay informed about NAV updates, as...

Continue Reading
Orvana Minerals Corp. Reports Financial Results for Q1 FY2026

Updated Category News Views 191

Orvana Minerals Corp. Financial Performance Overview TSX:ORV Orvana Minerals Corp. (TSX: ORV) has recently disclosed its financial statements for the first quarter of the fiscal year 2026 through its subsidiary, Empresa Minera Paitití, S.A. (EMIPA). These unaudited results are now available for viewing on the Bolivian stock market. The disclosure marks an important...

Continue Reading